Abivax’s orally administered miRNA-124 enhancer, obefazimod, demonstrated significant clinical remission and response rates across large Phase 3 studies in moderately to severely active ulcerative colitis patients. The pooled placebo-adjusted remission rate at eight weeks was 16.4%, surpassing prior Phase 2 data, supporting the company’s plans to seek regulatory submissions in 2026. The new data position obefazimod as a potential first-in-class oral treatment in a lucrative inflammatory bowel disease market estimated to reach $30 billion by 2030, with analysts projecting peak sales around $4 billion.